- Home
- APVO vs VIVS Comparison
APVO vs VIVS Comparison
Compare APVO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- VIVS
- Stock Information
- Founded
- APVO 2016
- VIVS 2007
- Country
- APVO United States
- VIVS United States
- Employees
- APVO N/A
- VIVS N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APVO Health Care
- VIVS Health Care
- Exchange
- APVO Nasdaq
- VIVS Nasdaq
- Market Cap
- APVO 4.1M
- VIVS 4.7M
- IPO Year
- APVO N/A
- VIVS N/A
- Fundamental
- Price
- APVO $1.61
- VIVS $2.51
- Analyst Decision
- APVO Strong Buy
- VIVS
- Analyst Count
- APVO 1
- VIVS 0
- Target Price
- APVO $5,920.00
- VIVS N/A
- AVG Volume (30 Days)
- APVO 162.7K
- VIVS 763.1K
- Earning Date
- APVO 11-06-2025
- VIVS 11-07-2025
- Dividend Yield
- APVO N/A
- VIVS N/A
- EPS Growth
- APVO N/A
- VIVS N/A
- EPS
- APVO N/A
- VIVS N/A
- Revenue
- APVO N/A
- VIVS $142,000.00
- Revenue This Year
- APVO N/A
- VIVS $42.38
- Revenue Next Year
- APVO N/A
- VIVS $15.42
- P/E Ratio
- APVO N/A
- VIVS N/A
- Revenue Growth
- APVO N/A
- VIVS 94.52
- 52 Week Low
- APVO $1.54
- VIVS $1.41
- 52 Week High
- APVO $381.10
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- APVO 28.32
- VIVS 63.18
- Support Level
- APVO $1.56
- VIVS $1.83
- Resistance Level
- APVO $1.73
- VIVS $3.10
- Average True Range (ATR)
- APVO 0.14
- VIVS 0.33
- MACD
- APVO 0.02
- VIVS 0.06
- Stochastic Oscillator
- APVO 11.29
- VIVS 57.25
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.